This database contains 168 studies, archived under the term: "adverse effects"
Click here to filter this large number of results.
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial
Coric, Vladimir,
Salloway, Stephen,
van Dyck, Christopher H.,
Dubois, Bruno,
Andreasen, Niels,
Brody, Mark,
Curtis, Craig,
Soininen, Hilkka,
Thein, Stephen,
Shiovitz, Thomas,
Pilcher, Gary,
Ferris, Steven,
Colby, Susan,
Kerselaers, Wendy,
Dockens, Randy,
Soares, Holly,
Kaplita, Stephen,
Luo, Feng,
Pachai, Chahin,
Bracoud, Luc,
Mintun, Mark,
Grill, Joshua D.,
Marek, Ken,
Seibyl, John,
Cedarbaum, Jesse M.,
Albright, Charles,
Feldman, Howard H.,
Berman, Robert M.
Importance: Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in clinical trials. To our knowledge, this is the first report of a randomized trial to prospectively enrich a study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria and mild […]
Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17β-estradiol versus conjugated equine estrogens
Wroolie, Tonita E.,
Kenna, Heather A.,
Williams, Katherine E.,
Powers, Bevin N.,
Holcomb, Megan,
Khaylis, Anna,
Rasgon, Natalie L.
Objective: Much controversy exists and many questions remain unanswered about the effects of hormone therapy (HT) on cognition in postmenopausal women. There is growing evidence suggesting that HT compounds containing conjugated equine estrogen (CEE) have negative effects on cognition whereas 17β-estradiol (17β-E) either has positive or neutral effects. The present study sought to further examine […]
Study of the effects of vinpocetin on cognitive functions
Introduction: Chronic cerebral hypoperfusion is a risk factor for the development of certain types of dementia. Mild cognitive impairment is a stage of predementia condition, because the symptoms are similar but not as severe as the symptoms in patients with dementia. Vinpocetine, due to its complex mechanism of action, has an important role in the […]
Pilot study of granulocyte-colony stimulating factor for treatment of Alzheimer’s disease
Sanchez-Ramos, Juan,
Cimino, Cynthia,
Avila, Ross,
Rowe, Amanda,
Chen, Ren,
Whelan, Glenn,
Lin, Xiaoyang,
Cao, Chuanhai,
Ashok, Raj
Human granulocyte colony-stimulating-factor (G-CSF) is widely used for treatment of neutropenia and to mobilize stem/progenitor cells for bone marrow transplantation. In studies of thousands of healthy donor subjects treated with G-CSF to mobilize stem/progenitor cells, the side-effect profile has been reported to be mild and reversible. In pre-clinical studies, G-CSF was reported to improve spatial […]
The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study
Padala, Kalpana P.,
Padala, Prasad R.,
McNeilly, Dennis P.,
Geske, Jenenne A.,
Sullivan, Dennis H.,
Potter, Jane F.
Background: Statins are well-known for their cardiovascular benefits. However, the cognitive effects of statins are not well understood. We hypothesized that individuals with preexisting dementia would be more vulnerable to statin-related cognitive effects.; Objective: The aim of this study was to evaluate the impact on cognition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statin) discontinuation and rechallenge […]
Alzheimer’s disease: is pacemaker implantation safe?
Osmonov, Damirbek,
Ozcan, Kazim Serhan,
Altay, Servet,
Erdinler, Izzet,
Yildirim, Ersin,
Türkkan, Ceyhan,
Canga, Yigit,
Alper, Ahmet Taha,
Cakmak, Nazmiye,
Gürkan, Kadir
Aim: To evaluate the safety of pacemaker implantation in patients with Alzheimer’s disease (AD).; Methods: We reviewed all cases admitted to our institution between January 2008 and June 2009, with symptomatic bradyarrhythmia for whom a permanent pacemaker was implanted. Beginning in June 2009, we prospectively collected data from all patients with the same diagnosis and […]
Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia
Herrmann, Nathan,
Black, Sandra E.,
Chow, Tiffany,
Cappell, Jaclyn,
Tang-Wai, David F.,
Lanctôt, Krista L.
Objectives: The purposes of this study were first, to evaluate the effectiveness of citalopram in treating behavioral disturbances in frontotemporal dementia (FTD) subjects and second, to determine whether an association exists between serotonergic function, as determined by a neuroendocrine challenge, and treatment response.; Design: Single-dose citalopram (30 mg per os) challenge followed by a 6-week […]
Relapse risk after discontinuation of risperidone in Alzheimer’s disease
Devanand, D. P.,
Mintzer, Jacobo,
Schultz, Susan K.,
Andrews, Howard F.,
Sultzer, David L.,
de la Pena, Danilo,
Gupta, Sanjay,
Colon, Sylvia,
Schimming, Corbett,
Pelton, Gregory H.,
Levin, Bruce
Background: Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.; Methods: Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a […]